TransMedics Group (NASDAQ:TMDX) Trading Up 6.3% – What’s Next?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price was up 6.3% during mid-day trading on Monday . The company traded as high as $74.72 and last traded at $75.7490. Approximately 120,398 shares were traded during trading, a decline of 89% from the average daily volume of 1,089,183 shares. The stock had previously closed at $71.23.

Analyst Ratings Changes

A number of research firms have commented on TMDX. TD Cowen restated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research report on Wednesday, July 1st. Stifel Nicolaus raised their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Piper Sandler reduced their target price on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Needham & Company LLC decreased their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, TransMedics Group presently has an average rating of “Hold” and an average price target of $134.50.

TransMedics Group Trading Up 7.6%

The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The stock has a market cap of $2.65 billion, a P/E ratio of 17.39 and a beta of 1.89. The business’s fifty day simple moving average is $71.52 and its 200 day simple moving average is $106.24.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same period in the prior year, the firm posted $0.70 earnings per share. The company’s revenue was up 21.2% on a year-over-year basis. As a group, analysts expect that TransMedics Group, Inc. will post 1.92 EPS for the current year.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently made changes to their positions in TMDX. Harvest Fund Management Co. Ltd acquired a new position in shares of TransMedics Group during the third quarter valued at $29,000. North Star Investment Management Corp. acquired a new stake in TransMedics Group in the first quarter worth about $30,000. Ascentis Independent Advisors bought a new stake in TransMedics Group during the 1st quarter worth about $30,000. Allworth Financial LP lifted its position in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the period. Finally, FNY Investment Advisers LLC acquired a new position in TransMedics Group during the 3rd quarter valued at about $34,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.